Brief: Alligator Bioscience: Primary Endpoint Of Optimize-1 Trial Was Met

Alligator Bioscience AB

20/06/2024 08:16

June 20 (Reuters) - Alligator Bioscience AB  ATORX.ST :
    * PRIMARY ENDPOINT OF OPTIMIZE-1 TRIAL WAS MET, WITH
OBJECTIVE
RESPONSE RATE (ORR) OF 40.4% IN 57 EVALUABLE PATIENTS

Source text for Eikon:  ID:nMFN7L7qMV 
Further company coverage:  ATORX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))